Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
HQY Catalyst Timeline
Dated clinical, regulatory and corporate events for HealthEquity, Inc
Past FDA Catalysts and PDUFA Decisions
How HQY actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Drug Pipeline Intelligence
No drug pipeline
HealthEquity, Inc is a services and tools company (CRO, lab tools or healthcare services). The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every HQY program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Rajasekar SunilOfficer (EVP Chief Prod & Strat Officer) | Buy | 108 53,405 held | $90.33 | 10/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in HQY
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Avidity Partners | 0.4 % (-20 %) | 1.55 M | 16.90 K | -33.2% ( -8.40 K) |
Ownership Trends
HQY Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How HQY ranks across every disease it competes in
HQY News
HealthEquity Schedules Third Quarter Earnings Release Date
HealthEquity, Inc. announced its third quarter earnings release for fiscal 2027, scheduled for December 1, 2026. Following the release, a conference call will be held at 4:30 p.m. ET to discuss the results. The company is a leader in health savings accounts and consumer-directed benefits.
Read more →HealthEquity Appoints Moody’s CFO Noémie Heuland to Board of Directors
HealthEquity has appointed Noémie Heuland, CFO of Moody's Corporation, to its Board of Directors effective September 24, 2026. Heuland will also participate in the Audit and Risk Committee and Cybersecurity and Technology Committee. Her expertise in finance and technology is expected to support HealthEquity's growth strategy and mission to enhance healthcare management for consumers.
Read more →HealthEquity Reports Second Quarter Ended July 31, 2026 Financial Results
HealthEquity reported strong financial results for the second quarter ended July 31, 2026, with a 10% increase in net income to $65.6 million and an 8% rise in revenue to $350.7 million. The company achieved a record Adjusted EBITDA margin of 48% and total HSA assets increased by 14%. Management has raised its fiscal 2027 guidance, reflecting confidence in ongoing growth.
Read more →HealthEquity Announces Second Quarter Earnings Release Date and Investor Conference Schedule
HealthEquity, Inc. has announced the release date for its second quarter fiscal 2027 earnings, set for August 27, 2026. Following the release, a conference call will be held to discuss the results. The company also plans to engage with investors at upcoming conferences, highlighting its position as a leader in health savings accounts.
Read more →One in Three Americans Delay Medical Care Due to Cost, HealthEquity Research Finds
HealthEquity's latest research reveals that over one-third of Americans delay medical care due to costs, highlighting ongoing healthcare affordability issues. The survey indicates that while understanding of benefits has improved, financial preparedness has declined. Notably, younger workers and those with chronic conditions are more affected. Health Savings Accounts (HSAs) appear to enhance financial readiness and security for users.
Read more →HealthEquity Reports First Quarter Ended April 30, 2026 Financial Results; Raises Guidance
HealthEquity reported first-quarter net income of $69.4 million, a 29 percent increase from the prior year. Adjusted EBITDA rose 17 percent to $164.5 million, while revenue grew 7 percent to $354.6 million. The company also raised its fiscal 2027 guidance and authorized an additional $1.0 billion for share repurchases. Total HSA assets reached $37.1 billion, reflecting a 19 percent year-over-year growth.
Read more →HealthEquity Announces First Quarter Earnings Release Date and Investor Conference Schedule
HealthEquity, Inc. announced the release date for its first quarter fiscal 2027 earnings, set for May 28, 2026. Following the earnings release, a conference call will be held to discuss the results. The company also plans to engage with investors at various upcoming conferences, emphasizing its commitment to transparency and investor relations.
Read more →HealthEquity Appoints Sanford Health CEO Bill Gassen to Board of Directors
HealthEquity has appointed Bill Gassen, CEO of Sanford Health, to its board of directors, effective March 26, 2026. Gassen will also participate in the Audit and Risk Committee and the Talent, Compensation and Culture Committee. His extensive experience in healthcare leadership is expected to bolster HealthEquity's efforts in helping consumers manage healthcare costs.
Read more →HealthEquity Reports Record Revenue, Earnings and New HSAs From Sales for Fourth Quarter and Year Ended January 31, 2026, Resulting in Raised Fiscal 2027 Outlook
HealthEquity reported record fiscal 2026 revenue of $1.31 billion and net income of $215.2 million. The company raised its fiscal 2027 outlook after adding one million new HSAs for the second consecutive year. Adjusted EBITDA grew 20% to $566.0 million, while total HSA assets increased 14% to $36.5 billion. Management expects 2027 revenue to reach between $1.405 billion and $1.415 billion.
Read more →HealthEquity Delivers Record Q4 and Standout Fiscal 2026 Sales Metrics
HealthEquity reported HSA assets reached $36.5 billion in fiscal 2026, a 14 percent increase from the prior year. The company also closed with 10.6 million HSAs, up 7 percent year over year. Fourth-quarter new HSA sales from accounts rose 17 percent compared to the same period last year. Management reaffirmed its guidance for the current and upcoming fiscal years.
Read more →HealthEquity Announces Fiscal Year 2027 Outlook Presentation at J.P. Morgan Healthcare Conference
HealthEquity, the largest HSA custodian in the U.S., has announced its fiscal year 2027 outlook, projecting revenues between $1.38 billion and $1.41 billion. The company reaffirmed its guidance for FY 2026 and highlighted its efforts in modernizing operations and enhancing security. HealthEquity will present these insights at the upcoming J.P. Morgan Healthcare Conference.
Read more →Young Americans Lead in HSA Adoption But Carry Heaviest Economic Burden, HealthEquity Research Finds
HealthEquity's Healthcare Affordability Pulse survey reveals that younger Americans, particularly Gen Z and Millennials, are leading in Health Savings Account (HSA) adoption while facing significant economic anxiety. Despite their proactive approach to healthcare savings, they report higher financial stress, which negatively impacts their workplace performance. The survey highlights the need for better education and employer support to enhance financial security.
Read more →HealthEquity Reports Third Quarter Ended October 31, 2025 Financial Results
HealthEquity reported third-quarter revenue of $322.2 million, a 7 percent increase from the prior year. Net income per diluted share rose to $0.59 from $0.06 a year ago. Non-GAAP net income per diluted share increased 29 percent to $1.01. Total HSA assets grew 15 percent to $34.4 billion during the quarter.
Read more →HealthEquity to Enhance Member Experience with Agentic AI
HealthEquity, Inc. has announced the deployment of agentic AI capabilities to enhance member experience. This technology aims to provide personalized support through natural conversations across various channels. The initiative is part of a broader commitment to leveraging technology for improved member outcomes, with a phased rollout beginning in November 2025. HealthEquity has previously implemented several AI-powered solutions to streamline processes and enhance customer engagement.
Read more →HealthEquity Announces Third Quarter Earnings Date
HealthEquity, Inc. (NASDAQ: HQY) has announced the release date for its third quarter fiscal 2026 earnings, set for December 3, 2025. Following the earnings report, management will host a conference call to discuss the financial results. The company administers HSAs for over 17 million accounts, emphasizing its commitment to enhancing consumer healthcare.
Read more →HealthEquity Introduces GLP-1 Telehealth and Direct HSA Enrollment Platforms
HealthEquity has launched two new initiatives aimed at improving access to affordable healthcare solutions. The first is a GLP-1 telehealth platform that connects HSA members with weight management medications. The second is a direct HSA enrollment platform, allowing individuals to open HSAs directly, particularly benefiting those newly eligible under recent ACA changes.
Read more →HealthEquity Strengthens Executive Leadership Team with Strategic Appointments to Drive Growth and Innovation
HealthEquity, Inc. has appointed Mukund Ramachandran as Chief Marketing Officer and Garett Kitch as Senior Vice President of Client Sales & Relationship Management. These appointments aim to enhance the company's strategic vision and capitalize on new market opportunities following recent federal legislation that expands HSA eligibility. The leadership changes are expected to strengthen HealthEquity's market position and drive innovation.
Read more →HealthEquity Reports Second Quarter Ended July 31, 2025 Financial Results
HealthEquity reported second quarter revenue of $325.8 million, a 9% increase from the prior year period. Net income rose 67% to $59.9 million, while non-GAAP net income grew 24% to $94.6 million. Adjusted EBITDA increased 18% to $151.1 million. The company also repurchased 0.7 million shares for $66.0 million during the quarter.
Read more →HealthEquity's AI-Powered Tool Recognized for Innovation in Streamlining Benefits Education
HealthEquity's AI-powered tool, HSAnswers, has been recognized with several awards for its innovative approach to benefits education. Launched in October 2024, it provides personalized responses to consumer-directed benefits inquiries. The tool has facilitated numerous conversations, addressing critical questions about health savings accounts and other benefits. HealthEquity aims to further enhance HSAnswers with more sophisticated features.
Read more →